Immunological response to oxidized LDL occurs in association with oxidative DNA damage independently of serum LDL concentrations in dyslipidemic patients

被引:34
作者
Inoue, T
Inoue, K
Maeda, H
Takayanagi, K
Morooka, S
机构
[1] Dokkyo Univ, Sch Med, Koshigaya Hosp, Dept Cardiol, Koshigaya City, Saitama 3438555, Japan
[2] TFB Inc, Dept Technol, Tokyo, Japan
关键词
oxidized LDL; antibody; 8-OHdG; oxidative DNA damage; dyslipidemia;
D O I
10.1016/S0009-8981(00)00426-5
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Oxidative modification of LDL induces immunogenic epitopes in the LDL molecule, and the presence of antibodies against oxidized LDL (anti-Ox-LDL) has been demonstrated in human sera. However, little is known about the clinical significance of anti-Ox-LDL. To elucidate a clinical relationship between the immunological response to oxidized LDL and cellular oxidative stress, we measured serum titers of anti-Ox-LDL in 45 unselected patients with hypercholesterolemia and serum 8-hydroxy-2 ' -deoxyguanosine (8-OHdG), considered a biomarker of the oxidative damage to DNA. The anti-Ox-LDL titer was not correlated with the serum LDL-C concentration, but was correlated with the 8-OHdG concentration (r=0.300, P<0.05) in a simple linear regression. Multiple regression analysis indicated that 8-OHdG was independently correlated with anti-Ox-LDL (r=0.429, P<0.05), but no other variables, including LDL-C concentrations and smoking habit, were correlated with anti-Ox-LDL. In 16 subgroup patients, the concentrations of TC, TG and LDL-C decreased and the HDL-C concentration increased after cholesterol-lowering therapy with fluvastatin. In addition, both the anti-Ox LDL titer (14.0 +/-9.5 to 11.4 +/-6.6 AcU/ml, P<0.05) and the 8-OHdG concentration (1.19<plus/minus>0.41 to 0.85 +/-0.43 ng/ml, P<0.05) also decreased after fluvastatin therapy. The immunological response to LDL oxidation on vascular wall tissues or cells appear to occur in association with oxidative DNA damage. The measurement of anti-Ox-LDL may be a useful indicator for lipid-lowering therapy. <(c)> 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:115 / 121
页数:7
相关论文
共 32 条
  • [1] ALLAIN CC, 1974, CLIN CHEM, V20, P470
  • [2] AUTOANTIBODIES AGAINST OXIDATIVELY MODIFIED LOW-DENSITY LIPOPROTEINS IN NIDDM
    BELLOMO, G
    MAGGI, E
    POLI, M
    AGOSTA, FG
    BOLLATI, P
    FINARDI, G
    [J]. DIABETES, 1995, 44 (01) : 60 - 66
  • [3] PATIENTS WITH EARLY-ONSET PERIPHERAL VASCULAR-DISEASE HAVE INCREASED LEVELS OF AUTOANTIBODIES AGAINST OXIDIZED LDL
    BERGMARK, C
    WU, R
    DEFAIRE, U
    LEFVERT, AK
    SWEDENBORG, J
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (04) : 441 - 445
  • [4] PREECLAMPSIA AND SERUM ANTIBODIES TO OXIDIZED LOW-DENSITY-LIPOPROTEIN
    BRANCH, DW
    MITCHELL, MD
    MILLER, E
    PALINSKI, W
    WITZTUM, JL
    [J]. LANCET, 1994, 343 (8898) : 645 - 646
  • [5] Chait A, 1992, CURR OPIN LIPIDOL, V3, P389
  • [6] PREDISPOSITION TO LDL OXIDATION IN PATIENTS WITH AND WITHOUT ANGIOGRAPHICALLY ESTABLISHED CORONARY-ARTERY DISEASE
    COMINACINI, L
    GARBIN, U
    PASTORINO, AM
    DAVOLI, A
    CAMPAGNOLA, M
    DESANTIS, A
    PASINI, C
    FACCINI, GB
    TREVISAN, MT
    BERTOZZO, L
    PASINI, F
    LOCASCIO, V
    [J]. ATHEROSCLEROSIS, 1993, 99 (01) : 63 - 70
  • [7] MALONDIALDEHYDE ALTERATION OF LOW-DENSITY LIPOPROTEINS LEADS TO CHOLESTERYL ESTER ACCUMULATION IN HUMAN MONOCYTE-MACROPHAGES
    FOGELMAN, AM
    SHECHTER, I
    SEAGER, J
    HOKOM, M
    CHILD, JS
    EDWARDS, PA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (04): : 2214 - 2218
  • [8] FOSSATI P, 1982, CLIN CHEM, V28, P2077
  • [9] Gutteridge J M, 1986, Free Radic Res Commun, V1, P173, DOI 10.3109/10715768609083149
  • [10] CELLULAR MECHANISMS FOR THE OXIDATIVE MODIFICATION OF LIPOPROTEINS - IMPLICATIONS FOR ATHEROGENESIS
    HEINECKE, JW
    [J]. CORONARY ARTERY DISEASE, 1994, 5 (03) : 205 - 210